参考文献:
[1]GARCIA-TSAO G, PARIKH CR, VIOLA A. Acute kidney injury in cirrhosis[J]. Hepatology, 2008, 48(6): 2064-2077.
[2]XIONG HF, LIU JY. Research progress on hepatorenal syndrome[J/CD]. Chin J Liver Dis (Electronic Version), 2017, 9(1): 1-6. (in Chinese)
熊号峰, 刘景院. 肝肾综合征研究进展[J/CD]. 中国肝脏病杂志(电子版), 2017, 9(1): 1-6.
[3]ZHAGN T, MEI CL. Acute renal in jury in the patients with liver cirrhosis[J]. Chin Hepatol, 2009, 14(3): 234-237. (in Chinese)
张彤, 梅长林. 肝硬化患者的急性肾损伤[J]. 肝脏, 2009, 14(3): 234-237.
[4]KHWAJA A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-184.
[5]European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460.
[6]BELCHER JM, EDELSTEIN CL, PARIKH CR. Clinical applications of biomarkers for acute kidney injury[J]. Am J Kidney Dis, 2011, 57(6): 930-940.
[7]BELCHER JM, SANYAL AJ, PEIXOTO AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury[J]. Hepatology, 2014, 60(2): 622-632.
[8]HUELIN P, SOL E, ELIA C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: A prospective study[J]. Hepatology, 2019, 70(1): 319-333.
[9]SALERNO F, GERBES A, GINS P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J]. Gut, 2007, 56(9): 1310-1318.
[10]DIAMOND JR, YOBURN DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium[J]. Ann Intern Med, 1982, 96(5): 597-600.
[11]Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. (in Chinese)
中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863.
[12]NAVASA M, FOLLO A, FILELLA X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality[J]. Hepatology, 1998, 27(5): 1227-1232.
[13]MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437. e1-9.
[14]MAIWALL R, CHANDEL SS, WANI Z, et al. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis[J]. Dig Dis Sci, 2016, 61(3): 920-929.
[15]SHAH N, MOHAMED FE, JOVER-COBOS M, et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis[J]. Liver Int, 2013, 33(3): 398-409.
[16]SHAH N, DHAR D, EL ZAHRAA MOHAMMED F, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression[J]. J Hepatol, 2012, 56(5): 1047-1053.
[17]GOMEZ H, INCE C, de BACKER D, et al. A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury[J]. Shock, 2014, 41(1): 3-11.
[18]PIANO S, SCHMIDT HH, ARIZA X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1792-1800.e3.
[19]TRAWAL JM, PARADIS V, RAUTOU PE, et al. The spectrum of renal lesions in patients with cirrhosis: A clinicopathological study[J]. Liver Int, 2010, 30(5): 725-732.
[20]ARIZA X, SOL E, ELIA C, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis[J]. PLoS One, 2015, 10(6): e0128145.
[21]ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822.
[22]ANGELI P, GINS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974.
[23]SANYAL AJ, BOYER TD, FREDERICK RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies[J]. Aliment Pharmacol Ther, 2017, 45(11): 1390-1402.
[24]MARTN-LLAHí M, PPIN MN, GUEVARA M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study[J]. Gastroenterology, 2008, 134(5): 1352-1359.
[25]CAVALLIN M, KAMATH PS, MERLI M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial[J]. Hepatology, 2015, 62(2): 567-574.
[26]CAVALLIN M, PIANO S, ROMANO A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992.
[27]ALESSANDRIA C, OTTOBRELLI A, DEBERNARDI-VENON W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study[J]. J Hepatol, 2007, 47(4): 499-505.
[28]SCHRIER RW, GROSS P, GHEORGHIADE M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20): 2099-2112.
[29]GINS P, SCHRIER RW. Renal failure in cirrhosis[J]. N Engl J Med, 2009, 361(13): 1279-1290.
[30]GAUDRY S, HAJAGE D, SCHORTGEN F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit[J]. N Engl J Med, 2016, 375(2): 122-133.
[31]ZARBOCK A, KELLUM JA, SCHMIDT C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN randomized clinical trial[J]. JAMA, 2016, 315(20): 2190-2199.
[32]Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. (in Chinese)
中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425.
[33]BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J]. Liver Transpl, 2011, 17(11): 1328-1332.
[34]NADIM MK, SUNG RS, DAVIS CL, et al. Simultaneous liver-kidney transplantation summit: Current state and future directions[J]. Am J Transplant, 2012, 12(11): 2901-2908.
[35]NADIM MK, GENYK YS, TOKIN C, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: Acute tubular necrosis versus hepatorenal syndrome[J]. Liver Transpl, 2012, 18(5): 539-548.
[36]BOSSEN L, KRAG A, VILSTRUP H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology, 2016, 63(6): 1968-1976.
[37]LEBREC D, THABUT D, OBERTI F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis[J]. Gastroenterology, 2010, 138(5): 1755-1762.